Keytruda
Safety Classified by Officially
Keytruda Active substance Pembrolizumab Holder MSD Belgium BV/SRL Status Running Indication in combination with paclitaxel with or without bevacizumab, is indicated for the treatment of platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma in adults whose tumours express PD-L1 with a CPS ≥1 and who have received one or two prior treatment regimens. …
This is an extract. The publication continues at the source.
Read the original at the source: https://www.famhp.be/nl/menselijk_gebruik/geneesmiddelen/geneesmiddelen/onderzoek_ontwikkeling/gebruik_in_schrijnende_280
Officially imported this from Federal Agency for Medicines and Health Products (FAMHP)’s own source and shows an extract. If you work there, claiming the profile and verifying the domain lets you choose to show the full text here.
Provenance
- Organization
- Federal Agency for Medicines and Health Products (FAMHP) — imported from official source
- Official source
- https://www.famhp.be/en/rss.xml RSS
- Imported
- November 17, 2026 09:31
- Versions
- 1 recorded
- Identity
-
110445 at https://www.famhp.be